Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 5Neoplasms 3Ovarian Neoplasms 2Solid Tumors 1Solid Cancers 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 5Cisplatin 5Specimen Handling 4pembrolizumab 3Radiation 3motexafin gadolinium 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Fluorouracil 2Biopsy 2zimberelimab 1peposertib 1ipatasertib 1dl1520 1Surgical Procedures, Operative 1Semaxinib 1Protons 1Proton Therapy 1Platinum 1Pemetrexed 1NVP-BKM120 1L 778,123 1Immunohistochemistry 1Hyperthermia, Induced 1Gemcitabine 1Fluorodeoxyglucose F18 1Fluorescent Antibody Technique 1Flow Cytometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hypopharyngeal Neoplasms × ipatasertib × Clear all
NCT05172245 2026-05-18

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
46 enrolled
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡